Sign inJoin waitlistJoin the waitlist

DM

Dipenkumar Modi

Physician · Barbara Ann Karmanos Cancer Institute - Detroit

Credentials: · · · · ·

History

Barbara Ann Karmanos Cancer Institute - Detroit
2019–Present

Hematology and Medical Oncology
2015–2018
Internal Medicine
2012–2015
Doctor of Medicine
2005–2009

Research

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Blood · 2021 · 151 citations
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
Blood · 2022 · 102 citations
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
Journal of Clinical Oncology · 2024 · 100 citations

Joseph Uberti
22 papers
Abinhav Deol
21 papers
Lois Ayash
19 papers
VR
Voravit Ratanatharathorn
19 papers
Asif Alavi
10 papers
Jeffery Auletta
10 papers
Monzr Al Malki
9 papers
Bronwen Shaw
8 papers
FK
Farhad Khimani
8 papers
Antonio Jimenez
7 papers
BS
Brian Shaffer
7 papers
Mahasweta Gooptu
7 papers

Clinical trials

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1
SciTech Development, Inc.
2023–2027
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Principal investigator · Recruiting · Phase 2
Dipenkumar Modi
2023–2028
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
Principal investigator · Withdrawn · Phase 2
Barbara Ann Karmanos Cancer Institute
2022–2025
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Principal investigator · Active not recruiting · Phase 2
Barbara Ann Karmanos Cancer Institute
2020–2026